Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1977 1
1987 1
1988 1
1989 1
1990 2
1991 1
1992 3
1993 3
1994 1
1996 4
1997 3
1998 1
1999 1
2000 2
2002 5
2003 3
2005 2
2007 1
2008 5
2009 5
2010 4
2011 5
2012 9
2013 6
2014 5
2015 4
2016 5
2017 8
2018 5
2019 9
2020 6
2021 7
2022 6
2023 7
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

116 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Portal hypertension, noncirrhotic, 2"
Page 1
Performance of non-invasive tests and histology for the prediction of clinical outcomes in patients with non-alcoholic fatty liver disease: an individual participant data meta-analysis.
Mózes FE, Lee JA, Vali Y, Alzoubi O, Staufer K, Trauner M, Paternostro R, Stauber RE, Holleboom AG, van Dijk AM, Mak AL, Boursier J, de Saint Loup M, Shima T, Bugianesi E, Gaia S, Armandi A, Shalimar, Lupșor-Platon M, Wong VW, Li G, Wong GL, Cobbold J, Karlas T, Wiegand J, Sebastiani G, Tsochatzis E, Liguori A, Yoneda M, Nakajima A, Hagström H, Akbari C, Hirooka M, Chan WK, Mahadeva S, Rajaram R, Zheng MH, George J, Eslam M, Petta S, Pennisi G, Viganò M, Ridolfo S, Aithal GP, Palaniyappan N, Lee DH, Ekstedt M, Nasr P, Cassinotto C, de Lédinghen V, Berzigotti A, Mendoza YP, Noureddin M, Truong E, Fournier-Poizat C, Geier A, Martic M, Tuthill T, Anstee QM, Harrison SA, Bossuyt PM, Pavlides M; LITMUS investigators. Mózes FE, et al. Lancet Gastroenterol Hepatol. 2023 Aug;8(8):704-713. doi: 10.1016/S2468-1253(23)00141-3. Epub 2023 Jun 5. Lancet Gastroenterol Hepatol. 2023. PMID: 37290471 Free article.
FINDINGS: Of 65 eligible studies, we included data on 2518 patients with biopsy-proven NAFLD from 25 studies (1126 [44.7%] were female, median age was 54 years [IQR 44-63), and 1161 [46.1%] had type 2 diabetes). After a median follow-up of 57 months [IQR 33-91], the compos …
FINDINGS: Of 65 eligible studies, we included data on 2518 patients with biopsy-proven NAFLD from 25 studies (1126 [44.7%] were female, medi …
"Porto-pulmonary hypertension: a comprehensive review".
Liberal R, Grant CR, Baptista R, Macedo G. Liberal R, et al. Clin Res Hepatol Gastroenterol. 2015 Apr;39(2):157-67. doi: 10.1016/j.clinre.2014.12.011. Epub 2015 Feb 7. Clin Res Hepatol Gastroenterol. 2015. PMID: 25659878 Review.
Porto-pulmonary hypertension (PoPH) is a rare but threatening vasculopathy, defined by the presence of pulmonary arterial hypertension (PAH) in the setting of portal hypertension. Although most commonly observed in cirrhotic patients, those with …
Porto-pulmonary hypertension (PoPH) is a rare but threatening vasculopathy, defined by the presence of pulmonary arterial hyperten …
Overlooked subclinical portal hypertension in non-cirrhotic NAFLD: Is it real and how to measure it?
Baffy G, Bosch J. Baffy G, et al. J Hepatol. 2022 Feb;76(2):458-463. doi: 10.1016/j.jhep.2021.09.029. Epub 2021 Oct 2. J Hepatol. 2022. PMID: 34606912 Review.
Clinical and experimental advances related to the detection, magnitude and pathobiology of subclinical portal hypertension in non-alcoholic fatty liver disease (NAFLD), primarily observed in the presence of non-alcoholic steatohepatitis (NASH), prompt us to r …
Clinical and experimental advances related to the detection, magnitude and pathobiology of subclinical portal hypertension in …
Non-invasive evaluation of portal hypertension using ultrasound elastography.
Berzigotti A. Berzigotti A. J Hepatol. 2017 Aug;67(2):399-411. doi: 10.1016/j.jhep.2017.02.003. Epub 2017 Feb 14. J Hepatol. 2017. PMID: 28223101 Review.
Portal hypertension (PH) leads to serious complications, such as bleeding from gastroesophageal varices, ascites and portosystemic encephalopathy in patients with chronic liver disease (CLD). ...
Portal hypertension (PH) leads to serious complications, such as bleeding from gastroesophageal varices, ascites and portosyst …
Histology of portal vascular changes associated with idiopathic non-cirrhotic portal hypertension: nomenclature and definition.
Guido M, Alves VAF, Balabaud C, Bathal PS, Bioulac-Sage P, Colombari R, Crawford JM, Dhillon AP, Ferrell LD, Gill RM, Hytiroglou P, Nakanuma Y, Paradis V, Quaglia A, Rautou PE, Theise ND, Thung S, Tsui WMS, Sempoux C, Snover D, van Leeuwen DJ; International Liver Pathology Study Group. Guido M, et al. Histopathology. 2019 Jan;74(2):219-226. doi: 10.1111/his.13738. Epub 2018 Oct 17. Histopathology. 2019. PMID: 30129657 Review.
Idiopathic non-cirrhotic portal hypertension (INCPH) is a rare vascular liver disease that has attracted new interest in recent years. It is characterised by clinical signs of portal hypertension in the absence of cirrhosis or severe fibrosis and any k …
Idiopathic non-cirrhotic portal hypertension (INCPH) is a rare vascular liver disease that has attracted new interest in recen …
Clinical features of idiopathic portal hypertension in China: A retrospective study of 338 patients and literature review.
Sun Y, Lan X, Shao C, Wang T, Yang Z. Sun Y, et al. J Gastroenterol Hepatol. 2019 Aug;34(8):1417-1423. doi: 10.1111/jgh.14552. Epub 2018 Dec 16. J Gastroenterol Hepatol. 2019. PMID: 30462857 Review.
BACKGROUND AND AIM: Idiopathic portal hypertension (IPH) refers to a relatively rare condition characterized by intrahepatic portal hypertension in the absence of underlying disease such as liver cirrhosis. ...Medication appears to be an important etio …
BACKGROUND AND AIM: Idiopathic portal hypertension (IPH) refers to a relatively rare condition characterized by intrahepatic …
Clinical Course of Porto-Sinusoidal Vascular Disease Is Distinct From Idiopathic Noncirrhotic Portal Hypertension.
Wöran K, Semmler G, Jachs M, Simbrunner B, Bauer DJM, Binter T, Pomej K, Stättermayer AF, Schwabl P, Bucsics T, Paternostro R, Lampichler K, Pinter M, Trauner M, Mandorfer M, Stift J, Reiberger T, Scheiner B. Wöran K, et al. Clin Gastroenterol Hepatol. 2022 Feb;20(2):e251-e266. doi: 10.1016/j.cgh.2020.11.039. Epub 2020 Dec 3. Clin Gastroenterol Hepatol. 2022. PMID: 33279774
BACKGROUND & AIMS: Porto-sinusoidal vascular disease (PSVD) was recently proposed as novel clinical entity characterized by typical histological changes with or without portal hypertension (PH) in the absence of cirrhosis. Thus, we aimed to describe clinical cha …
BACKGROUND & AIMS: Porto-sinusoidal vascular disease (PSVD) was recently proposed as novel clinical entity characterized by typical hist …
The impact of emricasan on chronic liver diseases: current data.
Lekakis V, Cholongitas E. Lekakis V, et al. Clin J Gastroenterol. 2022 Apr;15(2):271-285. doi: 10.1007/s12328-021-01585-2. Epub 2022 Jan 9. Clin J Gastroenterol. 2022. PMID: 35000120 Review.
In animal models, emricasan had a clear intrahepatic anti-apoptotic effect with consequent elimination of circulating pro-inflammatory cytokines and favorable impact in liver fibrogenesis and portal pressure. Even though, this intrahepatic drug effect confirmed in human cl …
In animal models, emricasan had a clear intrahepatic anti-apoptotic effect with consequent elimination of circulating pro-inflammatory cytok …
Clinical outcomes and prognostic factors in non-cirrhotic non-neoplastic patients with portal vein thrombosis: A single-centre experience.
Gioia S, Riggio O, Nardelli S, Ridola L, Marzano C. Gioia S, et al. Dig Liver Dis. 2023 Nov;55(11):1487-1495. doi: 10.1016/j.dld.2023.05.007. Epub 2023 May 23. Dig Liver Dis. 2023. PMID: 37230857
INTRODUCTION: The knowledge of natural history and prognostic factors of portal vein thrombosis (PVT) is still based on a limited number of studies. ...Eight patients died, 2 because of thrombotic events. There were no bleeding-related deaths. ...
INTRODUCTION: The knowledge of natural history and prognostic factors of portal vein thrombosis (PVT) is still based on a limited num …
Idiopathic portal hypertension: natural history and long-term outcome.
Siramolpiwat S, Seijo S, Miquel R, Berzigotti A, Garcia-Criado A, Darnell A, Turon F, Hernandez-Gea V, Bosch J, Garcia-Pagán JC. Siramolpiwat S, et al. Hepatology. 2014 Jun;59(6):2276-85. doi: 10.1002/hep.26904. Epub 2014 Feb 28. Hepatology. 2014. PMID: 24155091
Idiopathic portal hypertension (IPH) is a rare cause of intrahepatic portal hypertension. ...Mean duration of follow-up was 6.7 4.6 years. All patients had evidence of portal hypertension (PH) at diagnosis, and 42% were symptomatic. Varic …
Idiopathic portal hypertension (IPH) is a rare cause of intrahepatic portal hypertension. ...Mean duration of fo …
116 results